This article is more than 5 years old. Information may no longer be current.

Allergan’s sales increase almost 25% in third quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

IRVINE, Calif. — Pharmaceutical sales for Allergan increased 24.1% in the third quarter of 2003 compared with the same quarter 1 year ago. Overall net sales for the quarter were $443.3 million, including $21.4 million of nonpharmaceutical sales to Advanced Medical Optics, according to an earnings release from Allergan.

Highlights for the company during the quarter included launching Acular LS (ketorolac tromethamine) for the reduction of ocular pain and burning/stinging after corneal refractive surgery; receiving a positive opinion from European regulatory agencies for Vistabel (the European name for Allergan’s botulinum toxin type A product) in seven additional European countries, and filing a new drug application with U.S. regulators for a combined bimatoprost and timolol formulation for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension.

At the end of the quarter, Allergan announced its intentions to purchase Oculex, a company in codevelopment of posterior-segment products with Allergan. Also, Allergan received approval in the United States for Elestat (epinastine ophthalmic solution) for the prevention of itching associated with allergic conjunctivitis, according to the release. Elestat will be introduced in the United States during the first quarter of 2004, the release said.

For the fourth quarter, Allergan estimates total worldwide sales between $440 and $460 million, according to the news release. For the full year, the company has increased its sales expectations for its Alphagan franchise to somewhere between $255 million and $265 million. The company now expects its total pharmaceutical-only sales to increase $20 million to around $1.6 billion for the full year.